Thymic carcinoma associated with a high serum level of interleukin 6 diagnosed through the evaluation for asymptomatic elevation of acute-phase reactants

Internal Medicine

Volumn 37, Issue 4, 1998, Pages 414-416

  Ikeda, Takashi ^a   Kawakami, Kimihiro ^a   Fujita, Jiro ^a   Bandoh, Shuji ^a   Yamadori, Ichiro ^b   Takahara, Jiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

C reactive protein; Fever of unknown origin; Squamous cell carcinoma

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA;

ACUTE PHASE RESPONSE; ARTICLE; BLOOD LEVEL; CANCER SURGERY; CASE REPORT; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; THYMUS CANCER;

EID: 0031776605     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.414     Document Type: Article

References (13)

1. Fleck A. Clinical and nutritional aspects of changes in acute-phase proteins during inflammation. Proc Nutr Soc 48: 347, 1989.
2. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83, 1988.
3. Miki S, Iwano M, Miki Y, et al. Interleukin 6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. Febs Lett 250: 607, 1989.
4. Tamm I, Cardinale I, Krueger J, Murphy JS, May LT, Sehgal PB. Interleukin 6 decreases cell-cell association and increases motility of ductal breast carcinoma cells. J Exp Med 170: 1649, 1989.
5. Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB. Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135: 427, 1989.
6. Porgador A, Tzehoval E, Katz A, et al. Inlerleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52: 3679, 1992.
7. Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 89: 9215, 1992.
8. Takizawa H, Ohtoshi T, Ohta K, et al. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res 53: 4175, 1993.
9. Arias-Diaz J, Vara E, Torres-Melero J, et al. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 74: 1546, 1994.
10. Kirnbauer R, Kock A, Schwarz T, et al. IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol 142: 1922, 1989.
11. Tartour E, Gey A, Sastre-Garau X, et al. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Cancer Res 54: 6243, 1994.
12. van Gameren MM, Willemse PH, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 84: 1434, 1994.
13. Miles SA, Rezai AR, Salazar-Gonzalez JF, et al. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87: 4068, 1990.